Possis gets $15 million in private placement:
This article was originally published in Clinica
Possis Medical, whose primary product is the AngioJet thrombectomy device, has placed shares and warrants to a total of $15 million with private investors led by The Tail Wind Fund. Most are previous investors in the Minneapolis, Minnesota-based company. The funds strengthen the company's balance sheet, boost the US direct salesforce, improve manufacturing and facilitate new product development.